Over the past 12 months, 10 insiders at JOHNSON & JOHNSON filed 24 open-market SEC Form 4 transactions on JNJ: 1 purchase worth $258K and 23 sales worth $128.4M. Insiders have been net sellers over this period. The most recent filing was on Jul 20, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 20, 26 | Vanessa BroadhurstEVP, Global Corp Affairs | SELL | 23.1K | $251.27 | $5.8M |
| Jun 11, 26 | Kathryn E WengelEVP, Chief TO and Risk Officer | SELL | 10.0K | $241.15 | $2.4M |
| Feb 27, 26 | Robert J DeckerVP Corporate Controller | SELL | 4.1K | $247.87 | $1.0M |
| Feb 20, 26 | Timothy SchmidEVP, WW Chair, MedTech | SELL | 1.3K | $245.66 | $325K |
| Feb 18, 26 | Timothy SchmidEVP, WW Chair, MedTech | SELL | 13.6K | $244.53 | $3.3M |
| Feb 17, 26 | John C ReedEVP, Innovative Medicine, R&D | SELL | 29.9K | $243.00 | $7.3M |
| Feb 17, 26 | Vanessa BroadhurstEVP, Global Corp Affairs | SELL | 6.2K | $243.39 | $1.5M |
| Feb 17, 26 | James D. SwansonEVP, CIO | SELL | 20.5K | $242.70 | $5.0M |
| Feb 17, 26 | Joseph J WolkExec VP, CFO | SELL | 33.4K | $242.99 | $8.1M |
| Feb 13, 26 | James D. SwansonEVP, CIO | SELL | 22.2K | $243.76 | $5.4M |
| Jan 26, 26 | Joaquin DuatoCEO and Chairman of the Board | SELL | 51.2K | $221.48 | $11.3M |
| Nov 26, 25 | John G MorikisDirector | BUY | 1.3K | $206.15 | $258K |
| Oct 17, 25 | John C ReedEVP, Innovative Medicine, R&D | SELL | 21.7K | $192.71 | $4.2M |
| Sep 4, 25 | Jennifer L TaubertEVP, WWC. Innovative Medicine | SELL | 56.5K | $177.81 | $10.0M |
| Aug 22, 25 | Joaquin DuatoCEO and Chairman of the Board | SELL | 125.8K | $179.21 | $22.5M |
| Aug 15, 25 | Joseph J WolkExec VP, CFO | SELL | 16.8K | $176.91 | $3.0M |
| Jul 17, 25 | John C ReedEVP, Innovative Medicine, R&D | SELL | 19.1K | $163.55 | $3.1M |
| Feb 25, 25 | Robert J DeckerVP Corporate Controller | SELL | 7.0K | $165.88 | $1.2M |
| Feb 18, 25 | Timothy SchmidEVP, WW Chair, MedTech | SELL | 403 | $156.15 | $63K |
| Feb 7, 25 | Joseph J WolkExec VP, CFO | SELL | 13.0K | $153.89 | $2.0M |
| Dec 12, 24 | Mark A WeinbergerDirector | BUY | 1.0K | $147.22 | $147K |
| Aug 30, 24 | Robert J DeckerVP Corporate Controller | SELL | 5.6K | $165.06 | $930K |
| Apr 30, 24 | Eugene A. WoodsDirector | BUY | 100 | $145.53 | $15K |
| Mar 13, 24 | Vanessa BroadhurstEVP, Global Corp Affairs | SELL | 8.9K | $162.16 | $1.4M |
| Feb 9, 24 | Jennifer L TaubertEVP, WW Chair, Pharmaceuticals | SELL | 59.4K | $156.27 | $9.3M |
| Jul 26, 23 | William HaitSee Remarks | SELL | 14.7K | $172.00 | $2.5M |
| Jul 25, 23 | Peter FasoloExec VP, Chief HR Officer | SELL | 20.0K | $170.32 | $3.4M |
| Jun 12, 23 | Kathryn E WengelEVP, Chief TO and Risk Officer | SELL | 12.5K | $160.00 | $2.0M |
| Mar 6, 23 | James D. SwansonSee Remarks | SELL | 1.1K | $154.66 | $164K |
| Dec 13, 22 | Joseph J WolkExec VP, CFO | SELL | 12.9K | $179.62 | $2.3M |
| Nov 30, 22 | Ashley McEvoyEVP, WW Chair, MedTech | SELL | 71.9K | $176.09 | $12.6M |
| Nov 22, 22 | Jennifer L TaubertEVP, WW Chair, Pharmaceuticals | SELL | 76.9K | $176.78 | $13.6M |
| Nov 18, 22 | Robert J DeckerController, CAO | SELL | 16.9K | $175.00 | $3.0M |
| Nov 9, 22 | Kathryn E WengelEVP, Chief GSC Officer | SELL | 16.4K | $173.42 | $2.8M |
| Nov 4, 22 | Thibaut MongonExec VP, WW Chair, Consumer | SELL | 18.3K | $171.22 | $3.1M |
| Oct 24, 22 | Peter FasoloExec VP, Chief HR Officer | SELL | 1.9K | $171.36 | $328K |
| Oct 24, 22 | William HaitSee Remarks | SELL | 13.8K | $171.55 | $2.4M |
| Oct 19, 22 | Peter FasoloExec VP, Chief HR Officer | SELL | 2.2K | $164.50 | $367K |
| Jun 10, 22 | Kathryn E WengelEVP, Chief GSC Officer | SELL | 33.1K | $173.00 | $5.7M |
| May 26, 22 | Robert J DeckerController, CAO | SELL | 8.5K | $180.00 | $1.5M |
| Apr 21, 22 | William HaitSee Remarks | SELL | 22.6K | $183.58 | $4.1M |
| Mar 17, 22 | Thibaut MongonExec VP, WW Chair, Consumer | SELL | 6.6K | $176.28 | $1.2M |
| Mar 15, 22 | Robert J DeckerController, CAO | SELL | 2.8K | $175.51 | $483K |
| Dec 7, 21 | Robert J DeckerController, CAO | SELL | 5.0K | $163.21 | $816K |
Over the past 12 months, insiders at JOHNSON & JOHNSON filed 1 open-market purchase worth $258K and 23 sales worth $128.4M on JNJ, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 20, 26.
The largest recent open-market JNJ insider purchase in our data was $258K by John G Morikis, Director, filed on Nov 26, 25.
10 different insiders at JOHNSON & JOHNSON filed open-market SEC Form 4 transactions on JNJ over the last 12 months.
InsiderTape plots every JNJ insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every JOHNSON & JOHNSON insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →